Physician profile
Joseph Derit Te
NPI 1700946423
$29,355.87
in general payments reported to CMS, 2019-2025
83 companies · $5,316 in 2025
The $5,316 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,898 · 2020: $3,079 · 2021: $3,769 · 2022: $3,734 · 2023: $4,530 · 2024: $5,030 · 2025: $5,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $2,299 · Education: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,818.36 |
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Education | $758.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,164.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,129.61 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,681.60 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $1,624.93 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $1,429.12 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Pfizer INC. | $1,305.16 | 2019-2025 | |
| Astellas Pharma US INC | $1,158.57 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Janssen Biotech, INC. | $1,128.84 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Eisai INC. | $875.07 | 2019-2025 | |
| Incyte Corporation | $864.37 | 2019-2025 | Jakafi, Niktimvo, Monjuvi |
| Amgen INC. | $857.37 | 2019-2023 | Kyprolis, Lumakras, Blincyto |
| Seagen INC. | $815.15 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Daiichi Sankyo INC. | $707.66 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Lilly USA, LLC | $613.84 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $541.58 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Te listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.